Annals of Medicine Research and Public Health (ISSN: 2995-5955) | Volume 5, Issue 2 | Review Article | Open Access
Loso Judijanto*
IPOSS Jakarta, Indonesia
*Correspondence to: Loso Judijanto
Fulltext PDFDiabetic kidney disease (DKD) remains a major cause of chronic kidney disease and kidney failure despite substantial therapeutic advances. Renin–angiotensin system blockade, sodium–glucose cotransporter-2 inhibitors, non-steroidal mineralocorticoid-receptor antagonists, glucagon-like peptide-1 receptor agonists, and improved cardiometabolic management have transformed treatment, yet considerable residual renal risk persists. Palm-derived tocotrienols are biologically attractive adjunctive candidates because their reported activities intersect with oxidative stress, inflammation, mitochondrial dysfunction, endothelial injury, glycation, and fibrotic signalling. Importantly, human tocotrienol studies in DKD have generated an unresolved renal signal: creatinine-derived estimated glomerular filtration rate improved in a Phase IIb trial without a corresponding reduction in urinary albumin-to-creatinine ratio. This critical qualitative literature review evaluates whether such eGFR–albuminuria dissociation could reflect effects on kidney injury not adequately captured by albuminuria, including tubular, interstitial, microvascular, and mitochondrial pathways, while considering alternative explanations involving haemodynamics, creatinine biology, small-sample uncertainty, and endpoint variability. Contemporary evidence on non-albuminuric DKD, tubular biomarkers, eGFR slope, and modern cardiorenal pharmacotherapy is integrated with clinical and mechanistic tocotrienol research. Current evidence does not establish tocotrienols as disease-modifying DKD therapy. It does, however, provide sufficient mechanistic and preliminary clinical justification for rigorously designed adjunctive trials incorporating contemporary background therapy, standardized formulations, eGFR slope, serial albuminuria, cystatin C, tubular and inflammatory biomarkers, and longer-term kidney outcomes.
Diabetic kidney disease; Tocotrienols; Palm oil; Albuminuria; Estimated glomerular filtration rate; Oxidative stress; Renal fibrosis; Tubulointerstitial injury; Residual renal risk; Precision nephrology
Loso Judijanto. Renoprotection Beyond Albuminuria: Palm-Derived Tocotrienols, eGFR–UACR Dissociation, and Residual Kidney Risk in Contemporary Diabetic Kidney Disease—A Critical Review. Ann Med Res Pub Health. 2026;5(2):1-29.